Orchestra BioMed Q3 2023 Earnings Report $4.40 -0.20 (-4.35%) As of 03/28/2025 04:00 PM Eastern Earnings HistoryForecast Orchestra BioMed EPS ResultsActual EPS-$0.38Consensus EPS -$0.39Beat/MissBeat by +$0.01One Year Ago EPSN/AOrchestra BioMed Revenue ResultsActual Revenue$0.42 millionExpected Revenue$0.89 millionBeat/MissMissed by -$470.00 thousandYoY Revenue GrowthN/AOrchestra BioMed Announcement DetailsQuarterQ3 2023Date11/13/2023TimeN/AConference Call ResourcesPress ReleaseOBIO Earnings HistoryPowered by Remove Ads Orchestra BioMed Earnings HeadlinesOrchestra BioMed (NASDAQ:OBIO) Earns Buy Rating from Analysts at BTIG ResearchMarch 22, 2025 | americanbankingnews.comOrchestra BioMed initiated with a Buy at BTIGMarch 21, 2025 | markets.businessinsider.com7 Stocks Set to Win Big Under Trump’s America First Agenda 🚀The Trump economy is back in full force, and it’s creating huge opportunities for investors. With Trump pushing for lower taxes, fewer regulations, tariffs on foreign competitors, and domestic manufacturing dominance, some stocks are set to skyrocket in value—while others will be left behind. That’s why we put together this free report revealing the 7 MAGA stocks poised to thrive in 2025.March 31, 2025 | TradingTips (Ad)BTIG Initiates Coverage of Orchestra BioMed Holdings (OBIO) with Buy RecommendationMarch 21, 2025 | msn.comOrchestra BioMed to Present at Upcoming Investor ConferencesFebruary 20, 2025 | globenewswire.comOrchestra names Vivek Reddy as chairman of BACKBEAT study steering committeeFebruary 19, 2025 | markets.businessinsider.comSee More Orchestra BioMed Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Orchestra BioMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Orchestra BioMed and other key companies, straight to your email. Email Address About Orchestra BioMedOrchestra BioMed (NASDAQ:OBIO) operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.View Orchestra BioMed ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio?Analysts Lift Archer Aviation Stock Despite Earnings Miss Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
